What is MIST's current stock price?

MIST (Milestone Pharmaceuticals Inc.) is currently trading at $1.41 with a market cap of $121.1M.

What sector is Milestone Pharmaceuticals Inc. in?

Milestone Pharmaceuticals Inc. (MIST) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is MIST a good stock to buy?

Analysts have a Buy consensus on MIST with a price target of $7.33. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

MIST Milestone Pharmaceuticals Inc.

Healthcare

$1.41-7.24%ClosedMarket Cap: $121.1M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

5.10

P/S

67.88

EV/EBITDA

-2.97

DCF Value

$0.15

FCF Yield

-42.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

94.7%

Operating Margin

-3669.4%

Net Margin

-3832.0%

ROE

-339.4%

ROA

-35.3%

ROIC

-37.6%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$238.0K	$-26.1M	$—
Q4 null	$1.5M	$-17.4M	$—
FY null	$1.5M	$-63.1M	$—
Q3 null	$0.00	$-11.9M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$7.33

Target (Median)

$8.00

Target Range

$6.00 - $8.00

1 Strong Buy4 Buy1 Hold0 Sell0 Strong Sell

Wells FargoOverweight

2026-05-14

HC Wainwright & Co.Buy

2026-01-06

Wells FargoOverweight

2025-12-16

TD CowenBuy

2025-12-15

Trading Activity

Insider Trades

View All

Oliveto Josephdirector, officer: President and CEO

SellMon Apr 20

Sandoval David I.officer: GC & Chief Compliance Officer

SellMon Mar 23

Oliveto Josephdirector, officer: President and CEO

SellThu Feb 05

Nelson Jeffrey Edwardofficer: Chief Operating Officer

SellThu Feb 05

Muller Lorenzofficer: Chief Commercial Officer

SellThu Feb 05

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.04

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Peers